Ticagrelor is a first line therapy along with aspirin for patients undergoing primary PCI for
STEMI. However, many patients are still treated with fibrinolytic therapy and the safety and
efficacy of Ticagrelor has not been investigated in this patients population. The present
study is proposed to study the safety and efficacy of Ticagrelor in patients undergoing PCI
post fibrinolytic therapy for STEMI.
Phase:
Phase 3
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto